Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

nd vancomycin for intervening infections during the study.  The data indicated fidaxomicin was a superior therapy to vancomycin in preventing recurrence and in promoting global cure in patients requiring concomitant antibiotics.  The analysis from the Phase 3 trials indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin had a significantly lower CDI recurrence rate (17% vs. 28%, p=0.039) and had a significantly improved global cure rate (73% vs. 60%, p=0.013).  At the same time, among subjects who received no concomitant antibiotics, recurrence in vancomycin-treated subjects was double that of fidaxomicin-treated subjects (23% vs. 11.5%, p<0.001).

Ellie J. Goldstein, M.D., from the R.M. Alden Research Laboratory in Santa Monica, CA, presented data on the antimicrobial susceptibilities of C. difficile isolates to fidaxomicin, vancomycin, metronidazole, and rifaximin cultured from fecal specimens collected from patients at study entry and at failure/recurrence in Optimer's second Phase 3 clinical trial. The data showed that there was no relationship between MICs of baseline CDI isolates and clinical outcome for fidaxomicin but there was a one dilution difference for vancomycin between cure and failure.  The MIC90s were generally low for fidaxomicin,  vancomycin, and metronidazole but the BI isolates generally had higher MICs for the four drugs tested than the BK, CF, DH, G, J, and Y group isolates. No resistance to either fidaxomicin or vancomycin developed during the 10-day treatment in this or in the first Phase 3 trial.  Rifaximin resistant strains, 8.1% of all strains, were isolated in both treatment groups with MIC90s higher in treatment failures than cures.

In an oral presentation, Dale N. Gerding, M.D., an investigator from the Hines VA Hospital in Chicago, IL, presented data on the C. difficile strain types isolated in Optimer's two fidaxomicin
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ... financial results for the quarter ended April 30, 2011. ... Total operating expenses for the three and nine months ... compared to $3,000 and $15,000 for the three and ...
... BioXpress Therapeutics SA, a Swiss-based biotechnology company ... ) biosimilars announced today representatives from the Company ... Convention,s One-on-One Partnering Meetings being held Jun 27-30 ... Convention Center.   BioXpress Therapeutics currently ...
... Health Care Compliance Strategies, Inc. (HCCS) , the leading ... announced the release of a new online multimedia HIPAA ... . Responding to expanded HIPAA Privacy Rule and Security ... course designed to assist healthcare vendors in providing experience-based ...
Cached Biology Technology:OncoSec Medical Reports Third Quarter 2011 Financial Results 2OncoSec Medical Reports Third Quarter 2011 Financial Results 3OncoSec Medical Reports Third Quarter 2011 Financial Results 4BioXpress Therapeutics SA to Partner the 2011 BIO International Convention 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 3
(Date:7/10/2014)... , July 2, 2014 It is a ... announce the appointment of the world-renowned Thoracic and Cardiovascular ... Directors. Dr. Ginsburg, with over 34 years ... Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. ... the late 1980,s and is considered an expert in ...
(Date:7/10/2014)... , July 3, 2014 Research and ... of the "Global Gesture Recognition & Touch-Less ... Forecasts to 2020" report to their offering ... Global Gesture Recognition & Touch-Less Sensing Market to ... for a while, but the companies were unable ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... type 2 diabetes, not only do waistlines matter to women, but ... discovery by a team of Swedish researchers was just published online ... some women of normal weight develop type 2 diabetes, despite not ... between enlarged fat cells and the development of type 2 diabetes ...
... − One of the most intriguing developments in recent medical ... Since its detection in 1988, over 22,000 scholarly articles (about ... new class of drugs has been developed, and 25 Phase ... the scientific and medical communities involved in ET move towards ...
... their home and car energy use by as much as ... , They explain how in The CSIRO Home Energy Saving ... Your Carbon Footprint, launched today by Innovation Minister Senator Kim ... solution will require action from every individual," Senator Carr said. ...
Cached Biology News:Size of fat cells and waist size predict type 2 diabetes in women 2International conference on endothelin 2International conference on endothelin 3Energy experts helping Australian households reduce carbon emissions 2
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
ANTI STENOTROPHOMONAS MALTOPHILIA...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
Biology Products: